Following the announcement of the open access agreement between the DEAL Consortium and Elsevier last month, the Max Planck Society has now officially signed up as a participating institution, in a significant broadening of open access publication and reading options for Max Planck authors.

The agreement, which is in effect since 16 October, 2023 and runs through the end of 2028, allows authors across the Society to publish their research in Elsevier's journals—including well-known journal brands such as Cell Press and The Lancet—as Open Access articles under an open license retaining their copyright, with the publication fees being centrally covered by the Max Planck Digital Library. This comes in addition to the reestablishment of comprehensive reading access to virtually the entire Elsevier journal collection hosted on ScienceDirect.

Information for authors

DEAL-Elsevier agreement details